Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide-2,3,5,6-d4
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Imatinib-d4 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Imatinib-d4 usage and description
Imatinib D4 is a deuterated form of Imatinib, which is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other types of cancer. Imatinib D4 is chemically identical to Imatinib, except that it contains four deuterium atoms in place of hydrogen atoms. This isotopic substitution results in a slightly higher molecular weight, which can improve the drug's pharmacokinetics and pharmacodynamics.
Imatinib D4 works by inhibiting the activity of BCR-ABL, a fusion protein that is overproduced in CML and drives the growth of cancer cells. By blocking this protein, Imatinib D4 can slow or stop the proliferation of cancer cells, leading to remission or extended survival in many patients.
The usage of Imatinib D4 is similar to that of Imatinib, with the main difference being its isotopic composition. The drug is typically administered orally, in the form of tablets or capsules, with dosages varying depending on the patient's condition and response to treatment. Side effects of Imatinib D4 may include nausea, vomiting, diarrhea, muscle cramps, and fatigue.
In terms of chemical information, Imatinib D4 has a molecular formula of C29H29D4N7O and a molecular weight of 505.65 g/mol. It is a white to off-white powder that is insoluble in water but soluble in organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO). Imatinib D4 is stable under normal storage conditions and can be stored at room temperature for extended periods of time.
